NASDAQ:LYRA Lyra Therapeutics (LYRA) Stock Price, News & Analysis $0.26 -0.02 (-7.17%) (As of 11/1/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Lyra Therapeutics Stock (NASDAQ:LYRA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Lyra Therapeutics alerts:Sign Up Key Stats Today's Range$0.26▼$0.2950-Day Range$0.22▼$0.3452-Week Range$0.21▼$6.79Volume829,665 shsAverage Volume1.64 million shsMarket Capitalization$16.95 millionP/E RatioN/ADividend YieldN/APrice Target$4.50Consensus RatingHold Company OverviewLyra Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase III clinical trial; and LYR-220 for CRS patients with and without nasal polyps. It has a collaboration agreement with LianBio Inflammatory Limited to develop and commercialize LYR-210 in mainland China, Hong Kong, Taiwan, Macau, South Korea, Singapore, and Thailand. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.Read More… We recommended Nvidia in 2016, now we’re recommending this… (Ad)The AI boom is just getting started. And the real wealth has still to be made…You must read this new presentation from Porter Stansberry. Lyra Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks56th Percentile Overall ScoreLYRA MarketRank™: Lyra Therapeutics scored higher than 56% of companies evaluated by MarketBeat, and ranked 423rd out of 975 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingLyra Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, 4 hold ratings, and 1 sell rating.Amount of Analyst CoverageLyra Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Lyra Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Lyra Therapeutics are expected to grow in the coming year, from ($1.15) to ($0.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lyra Therapeutics is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lyra Therapeutics is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLyra Therapeutics has a P/B Ratio of 0.17. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Lyra Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.27% of the outstanding shares of Lyra Therapeutics have been sold short.Short Interest Ratio / Days to CoverLyra Therapeutics has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lyra Therapeutics has recently decreased by 24.91%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLyra Therapeutics does not currently pay a dividend.Dividend GrowthLyra Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.27% of the outstanding shares of Lyra Therapeutics have been sold short.Short Interest Ratio / Days to CoverLyra Therapeutics has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lyra Therapeutics has recently decreased by 24.91%, indicating that investor sentiment is improving significantly. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Lyra Therapeutics this week, compared to 1 article on an average week.Search Interest9 people have searched for LYRA on MarketBeat in the last 30 days. This is an increase of 800% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Lyra Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.69% of the stock of Lyra Therapeutics is held by insiders.Percentage Held by Institutions95.62% of the stock of Lyra Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Lyra Therapeutics' insider trading history. Receive LYRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address LYRA Stock News HeadlinesLyra Therapeutics, Inc. (NASDAQ:LYRA) Receives Consensus Rating of "Hold" from BrokeragesOctober 29, 2024 | americanbankingnews.comLyra Therapeutics, Inc. (LYRA)October 22, 2024 | finance.yahoo.com625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.November 2, 2024 | Crypto Swap Profits (Ad)Lyra Therapeutics completes Phase 3 trial enrollment for CRS treatmentOctober 17, 2024 | uk.investing.comLyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic RhinosinusitisOctober 15, 2024 | globenewswire.comLyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual MeetingsSeptember 27, 2024 | globenewswire.comLyra Therapeutics Insiders Still US$66k Away From Original Investment ValueAugust 22, 2024 | uk.finance.yahoo.comLyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 14, 2024 | globenewswire.comSee More Headlines LYRA Stock Analysis - Frequently Asked Questions How have LYRA shares performed this year? Lyra Therapeutics' stock was trading at $5.24 at the beginning of 2024. Since then, LYRA shares have decreased by 95.1% and is now trading at $0.2589. View the best growth stocks for 2024 here. How were Lyra Therapeutics' earnings last quarter? Lyra Therapeutics, Inc. (NASDAQ:LYRA) announced its earnings results on Wednesday, August, 14th. The company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.34) by $0.05. The firm earned $0.60 million during the quarter, compared to analyst estimates of $0.43 million. Lyra Therapeutics had a negative net margin of 5,570.88% and a negative trailing twelve-month return on equity of 102.22%. When did Lyra Therapeutics IPO? Lyra Therapeutics (LYRA) raised $52 million in an IPO on Friday, May 1st 2020. The company issued 3,500,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and William Blair served as the underwriters for the IPO and BTIG was co-manager. How do I buy shares of Lyra Therapeutics? Shares of LYRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Lyra Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Lyra Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), CrowdStrike (CRWD), ServiceNow (NOW) and Adobe (ADBE). Company Calendar Last Earnings8/14/2024Today11/02/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:LYRA CUSIPN/A CIK1327273 Webwww.lyratherapeutics.com Phone617-393-4600FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Stock Price Target$4.50 High Stock Price Target$11.00 Low Stock Price Target$0.50 Potential Upside/Downside+1,638.1%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-62,680,000.00 Net Margins-5,570.88% Pretax Margin-5,567.64% Return on Equity-102.22% Return on Assets-57.77% Debt Debt-to-Equity RatioN/A Current Ratio3.60 Quick Ratio3.60 Sales & Book Value Annual Sales$1.56 million Price / Sales10.86 Cash FlowN/A Price / Cash FlowN/A Book Value$1.56 per share Price / Book0.17Miscellaneous Outstanding Shares65,460,000Free Float62,387,000Market Cap$16.95 million OptionableOptionable Beta-0.02 A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:LYRA) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lyra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lyra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.